[Skip to Content]

Claim CME

Allergy and Clinical Immunology

Topical Therapies for Atopic Dermatitis

To identify the key insights or developments described in this article

1 Credit CME

JAMA

Published Online: October 27, 2023

JAMA Clinical Guidelines Synopsis

Article Information and Disclosures

Amy Z. Xu, MD, MA¹;

Jason T. Alexander, MD²

Author Affiliations

¹Department of Medicine, Section of Dermatology, University of Chicago, Chicago, Illinois
²Department of Medicine, University of Chicago, Chicago, Illinois

Read article on JAMA Network

Read Article Claim CME

Atopic dermatitis (AD) is a chronic inflammatory skin condition affecting approximately 10% of the US population. AD often occurs as a childhood disease in conjunction with allergies and asthma, but it can also persist into or arise de novo in adulthood. AD negatively affects quality of life, social interactions, and work productivity, with annual US health care costs exceeding $5.3 billion.¹ The current guideline provides recommendations on the management of AD in adults with both nonpharmacologic and pharmacologic topical therapies.²

Claim CME

Sign in to take quiz and track your certificates

Buy This Activity

Article Information

Corresponding Author: Amy Z. Xu, MD, MA, Section of Dermatology, University of Chicago Medicine, 5841 S Maryland Ave, MC5067, Chicago, IL 60637 (azxu@uchicago.edu).

Published Online: October 27, 2023. doi:10.1001/jama.2023.17719

Conflict of Interest Disclosures: None reported.

References

Drucker AM , Wang AR , Li WQ , et al. The burden of atopic dermatitis. J Invest Dermatol. 2017;137(1):26-30.PubMed Google Scholar Crossref

Sidbury R , Alikhan A , Bercovitch L , et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023:S0190.Google Scholar

Eichenfield LF , Miller BH . Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age. J Am Acad Dermatol. 2006;54(4):715-717.PubMed Google Scholar Crossref

Hanifin J , Gupta AK , Rajagopalan R . Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol. 2002;147(3):528-537.PubMed Google Scholar Crossref

Berth-Jones J , Damstra RJ , Golsch S , et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis. BMJ. 2003;326(7403):1367.PubMed Google Scholar Crossref

Hanifin JM , Ling MR , Langley R , et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients. J Am Acad Dermatol. 2001;44(1)(suppl):S28-S38.PubMed Google Scholar Crossref

Luger T , Van Leent EJ , Graeber M , et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001;144(4):788-794.PubMed Google Scholar Crossref

Kim BS , Howell MD , Sun K , et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572-582.PubMed Google Scholar Crossref

Papp K , Szepietowski JC , Kircik L , et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis. J Am Acad Dermatol. 2021;85(4):863-872.PubMed Google Scholar Crossref

Kim BS , Sun K , Papp K , et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305-1313.PubMed Google Scholar Crossref

AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
1.00 credit toward the CME of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.